Catalyst Pharmaceutical Partners, Inc.
Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction and obsessive-compulsive disorders. Its products include CPP-109, a chemical compound gamma-vinyl-GABA/vigabatrin, a Phase II clinical trial product for the treatment of cocaine addiction. The company also conducts a Phase II clinical trial of CPP-109 to evaluate its use in the treatment of methamphetamine addiction. In addition, it has a license agreement with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions.
Contact Details
Office Address
Catalyst Pharmaceutical Partners, Inc.
355 Alhambra Circle, Suite 1370
Coral Gables, FL, USA 33134
Phone: (305) 529-2522
Fax: (305) 529-0933
Executives
Co-Founder, Chairman, Chief Exec. Officer and Pres.
Mr. Patrick J. McEnany
Co-Founder & Director
Dr. Hubert E. Huckel